Conference Coverage
Researchers identify five cognitive phenotypes in MS
Clinical and imaging examinations suggest discrete profiles of cognitive dysfunction with distinct neuroanatomical foundations.
Conference Coverage
Masitinib impresses in nonactive progressive MS
The investigational drug has shown a positive result in slowing disability in patients with primary progressive and secondary progressive forms of...
Conference Coverage
Multiple sclerosis prodrome holds promise of earlier diagnosis
“There is now no doubt that there is an MS prodrome measurable by increased healthcare usage and lifestyle changes that are recognizable 5-10...
Conference Coverage
High plasma GFAP level predicts disability accumulation in secondary progressive MS
The GFAP level may be a stronger predictor in women and in patients with nonactive disease, compared with active disease.
Conference Coverage
App for MS aims to capture elusive signals of progression
Researchers in Switzerland argue for seeing MS as a continuum of disease that can progress with or without relapse. Their new smartphone-based app...
Conference Coverage
Satralizumab reduces risk of severe NMOSD relapse
The treatment also was linked to a lower likelihood of receiving acute relapse therapy, but the study’s sample size was low.
Conference Coverage
Cardiovascular risk factors linked to brain atrophy in MS
Even low levels of exposure to cardiovascular risk factors are important in MS and might affect brain atrophy—and therefore long-term disability—...
Conference Coverage
Lessons for patients with MS and COVID-19
Patients with MS and COVID-19 avoided disease reactivation with combined PCR-serology testing and continued MS therapies with good results.
Conference Coverage
Exposure to DMT may delay disability accumulation in primary progressive MS
Longer exposure to treatment is associated with a reduced risk of being restricted to a wheelchair in this patient population.
News
In MS, serious adverse effects are more common in rituximab versus ocrelizumab
Infection rates are high among reported AEs, and related deaths weren’t uncommon, researchers reported.
Conference Coverage
Smoking increases risk of high plasma NfL levels in patients with MS
Patients who have stopped smoking have notably lower risk that correlates to how long ago they quit.
News
Lowering rituximab dose in patients with MS proves safe and effective
Among study participants, no relapses occurred in the year after lowering rituximab dosage to 500 mg.
News
FDA approves ofatumumab (Kesimpta) for relapsing forms of MS
The first FDA-approved self-administered targeted B-cell therapy for MS is delivered via an autoinjector pen.
Conference Coverage
Influenza vaccine efficacy called undiminished in MS
Meta-analysis results are consistent with latest AAN immunization guideline.
Conference Coverage
CMSC MRI guidelines evolve into international consensus protocol
Internationally accepted consensus guidelines will improve lagging conformity with the recommendations.
News
Relapsing, progressive MS classifications should be abandoned
“The disease appears to be more of a continuum of disability progression, which is sometimes also accompanied by relapses.”
News
FDA approves Uplizna for treatment of anti-AQP4 antibody–positive NMOSD
Second FDA-approved therapy for neuromyelitis optica spectrum disorder offers patients additional treatment option.
Conference Coverage
-
Researchers identify five cognitive phenotypes in MS -
Masitinib impresses in nonactive progressive MS -
Multiple sclerosis prodrome holds promise of earlier diagnosis -
-
Multimedia
Question 1 of 5